Icometrix Gets First CPT III Code Issued by AMA for AI Brain MRI Software

Article

Reportedly receiving the first Current Procedural Terminology (CPT) III code from the American Medical Association (AMA) for artificial intelligence (AI)-enabled brain magnetic resonance imaging (MRI) software, Icometrix says its adjunctive quantification software can be utilized for diagnosis and assessment of conditions ranging from Alzheimer’s disease and epilepsy to stroke and dementia.

Creating a potential path for reimbursement, the American Medical Association (AMA) has issued a Current Procedural Terminology (CPT) III code for the use of icometrix’s artificial intelligence (AI)-powered brain magnetic resonance imaging (MRI) quantification software.

Icometrix, which has five Food and Drug Administration (FDA)-cleared AI software applications for brain MRI and computed tomography (CT), said the CPT III code is the first one issued for adjunctive AI quantification of brain MRI scans.

“Precision medicine is vital for improving treatment of neurological conditions, and especially for multiple sclerosis,” noted Tim Coetzee, PhD, the chief advocacy, services, and science officer at the National Multiple Sclerosis Society. “This recognition creates a path for icometrix’s innovative technology to be integrated into the management of multiple sclerosis (MS) and takes us one step closer to a future where precision medicine guides treatment decisions.”

Icobrain ms, one of the aforementioned AI software applications, facilitates objective quantification and tracking of white matter hyperintensities on FLAIR, TI MRI and contrast-enhanced T1 MRI, according to icometrix. The company added that its portfolio of AI-enabled neuroimaging software can be utilized in the diagnosis and assessment of treatment for conditions ranging from Alzheimer’s disease and MS to stroke and epilepsy.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
Related Content
© 2025 MJH Life Sciences

All rights reserved.